Evidence map›Paper›PMID 39564958›Full record

ArticleFEBS open bio2025

Unique pharmacological properties of etrasimod among S1P receptor modulators.

Ibragim Gaidarov, H Kiyomi Komori, Dariusz T Stepniak, Karin Bruinsma, Huong Dang, Xiaohua Chen, Todd Anthony, Joel Gatlin, Lisa Karimi-Naser, Anh-Tuan Ton and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ibragim GaidarovBeacon Discovery, San Diego, CA, USA.
H Kiyomi KomoriArena Pharmaceuticals, San Diego, CA, USA.
Dariusz T StepniakArena Pharmaceuticals, San Diego, CA, USA.
Karin BruinsmaBeacon Discovery, San Diego, CA, USA.
Huong DangBeacon Discovery, San Diego, CA, USA.
Xiaohua ChenBeacon Discovery, San Diego, CA, USA.
Todd AnthonyBeacon Discovery, San Diego, CA, USA.
Joel GatlinBeacon Discovery, San Diego, CA, USA.
Lisa Karimi-NaserArena Pharmaceuticals, San Diego, CA, USA.
Anh-Tuan TonAnaBios Corporation, San Diego, CA, USA.
Tim IndersmittenAnaBios Corporation, San Diego, CA, USA.
Paul E MillerAnaBios Corporation, San Diego, CA, USA.
Andre GhettiAnaBios Corporation, San Diego, CA, USA.
Najah Abi-GergesAnaBios Corporation, San Diego, CA, USA.
David UnettBeacon Discovery, San Diego, CA, USA.
Hussien Al-ShammaBeacon Discovery, San Diego, CA, USA.
Christopher J RabbatArena Pharmaceuticals, San Diego, CA, USA.
Catherine CrosbyArena Pharmaceuticals, San Diego, CA, USA.
John W AdamsArena Pharmaceuticals, San Diego, CA, USA.

Funding

Pfizer
6 · The paper itself

Abstract

Etrasimod (ADP334) is an oral, once-daily, selective sphingosine 1-phosphate (S1P)

Indexed as

OxadiazolesSphingosine 1 Phosphate Receptor ModulatorsAzetidinesBenzyl CompoundsFingolimod HydrochlorideHumansHuman Umbilical Vein Endothelial CellsIndansReceptors, LysosphingolipidSignal TransductionSphingosine-1-Phosphate Receptors2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino)ethanolAzetidinesBenzyl CompoundsFingolimod HydrochlorideIndansOxadiazolesozanimodReceptors, LysosphingolipidsiponimodSphingosine 1 Phosphate Receptor ModulatorsSphingosine-1-Phosphate Receptorsetrasimodpharmacodynamicspharmacokineticssphingosine 1‐phosphate receptor modulator

Identifiers

PMID39564958
PMCPMC11705451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.